"The problem of cash flow is severe with some of the subsidiaries like Bharat Coking Coal, Western Coalfields and Central Coalfields. They are facing a liquidity crunch to fulfil their statutory obligations like payment of salaries in the wake of low realisations," an official said. … [Read more...] about Coal India dues from state power gencos mount to Rs 22,000 crore amid tepid demand
Rs 27 crore
Google CEO Sundar Pichai on July 13 announced a $10 billion GoogleForIndia Digitisation Fund. Under the fund, Google will invest roughly Rs 75,000 crore in India over the next 5-7 years. "I am glad to announce – Google for India digitization fund – it's $10 billion dollars for India alone," Sundar Pichai said in a tweet. … [Read more...] about Sundar Pichai says Google will invest Rs 75,000 crore in India over next 5-7 years
As on May 31, 2020, Rossari Biotech had a range of 2,030 different products sold across these categories. The company manufactures majority of its products in-house from their manufacturing facility at Silvassa (which has 1.2 lakh MTPA capacity) and currently it is setting up another manufacturing facility at Dahej in Gujarat with a proposed installed capacity of 1,32,500 MTPA. … [Read more...] about Rossari Biotech IPO opens today, subscribed 34% so far on Day 1
All three options do look exciting but they cater to different segments of market participants and can't be bunched in one category. If someone wants to invest for long-term wealth creation, then ‘Bharat Bond ETF, Rosari Biotech, and Yes Bank IPO are preferred choice, filtered on the basis of wealth creation/protection of capital. … [Read more...] about Rossari Biotech IPO, Bharat Bond ETF & Yes Bank FPO: Where should investors put their money?
At the upper end of the price band, Rossari Biotech demands PE multiple of 31-33x FY20 fully diluted EPS, while its peers such as Aarti Industries, Fine Organics, Vinati Organics, Atul and Galaxy Surfactants are available at PE multiples of 31x, 35-36x, 31x, 21x and 24x FY20 fully diluted EPS respectively. … [Read more...] about Analysts say subscribe to Rossari Biotech IPO despite high valuation, here is why